Featured Solutions

  1. Safety Pharmacology Studies 1/9/2025

    Work with our safety pharmacology experts to design an ICH S7A and S7B-compliant program that optimizes resources and accelerates your drug development process.

  2. Biologics Safety Assessment 1/9/2025

    We conduct safety assessment studies of six months or longer, following ICH S6 guidelines, from single-dose acute to chronic studies in rodents and non-rodents.

  3. Small Molecule Safety Assessment 1/9/2025

    We collaborate closely to accelerate your timeline, completing the in vivo portion of your IND program for FDA submission in about six months or less.

  4. Preclinical Facilities 1/9/2025

    Our experts support your nonclinical journey with globally compliant solutions for small and large molecule studies, aiding your IND, CTA, NDA, or BLA submissions.

  5. Proactive Drug Development For Large Molecules 1/7/2025

    Streamline your large molecule drug development journey, from discovery to clinical trials and beyond, with integrated services designed to accelerate success.

  6. Your Top Partner For Ophthalmic Drug Development 4/9/2024

    As a leading partner in ocular therapy, Altasciences is at the forefront of ophthalmic drug development. Our integrated CRO/CDMO solutions can support your program from lead candidate selection to market. You will benefit from working with a single partner as your product advances through each phase of drug development—from prototype formulation through preclinical testing, to early phase clinical trials, and manufacturing. This could mean up to 40% in time savings.